Relationship between the suppressive actions on intestinal absorption and on cGMP production for the natriuretic peptide family in dogs.
1. The aim of this study was to investigate whether the suppressive effects of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) on net intestinal absorption were related to guanosine 3',5'-cyclic monophosphate (cGMP) production in the intestine. 2. We measured the plasma cGMP concentration of the arterial, jejunal and ileal venous blood after intravenous infusions of natriuretic peptides (97 pmol/kg per min for 30 min) in anaesthetized dogs. 3. The infusion of ANP increased cGMP concentration of the aortic blood by 49.9 +/- 9.0 (pmol/mL), BNP by 71.8 +/- 12.3 and CNP by 5.5 +/- 1.3. The increases in cGMP after ANP and BNP were larger than after CNP. The infusion of ANP increased jejunal arteriovenous differences in cGMP concentration by 69.9 +/- 3.5 (pmol/mL) and ileal arteriovenous differences by 8.7 +/- 3.2. In BNP infusion, the jejunal and ileal arteriovenous differences in cGMP concentration tended to increase by 15.6 +/- 5.8 (pmol/mL) and by 14.8 +/- 6.6 but neither were significant. CNP infusion did not change the jejunal and ileal arteriovenous differences in cGMP concentration. 4. These results suggest that, while the actions of ANP on intestinal absorption may be mediated by cGMP, those of BNP and CNP are not.
Kagawa
K
K
Department of Physiology, Kagawa Medical School, Japan.
Suzuki
S
S
Matsushita
K
K
Uemura
N
N
Morita
H
H
Hosomi
H
H
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D002712:Chlorides / Q000493:pharmacokinetics; D006152:Cyclic GMP / Q000096:biosynthesis* / Q000097:blood; D003864:Depression, Chemical; D004285:Dogs; D005260:Female; D007262:Infusions, Intravenous; D007408:Intestinal Absorption / Q000187:drug effects*; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D008297:Male; D020097:Natriuretic Peptide, Brain; D020098:Natriuretic Peptide, C-Type; D009419:Nerve Tissue Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D011506:Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D012964:Sodium / Q000493:pharmacokinetics; D015016:Yohimbine / Q000494:pharmacology
D002712:Chlorides; D009419:Nerve Tissue Proteins; D011506:Proteins; D020097:Natriuretic Peptide, Brain; D020098:Natriuretic Peptide, C-Type; D015016:Yohimbine; D001285:Atropine; D009320:Atrial Natriuretic Factor; D012964:Sodium; D006152:Cyclic GMP